Pharmaceutical Executive November 10, 2023
The global market for chikungunya virus vaccines is estimated to exceed $500 million annually by 2032.
The FDA has granted accelerated approval to Valneva’s Ixchiq, a single-dose, live-attenuated vaccine to prevent disease caused by chikungunya virus (CHIKV) in individuals aged 18 years and older with an increased risk of exposure to the virus.
The FDA action makes Ixchiq the first and only licensed CHIKV vaccine approved in the United States for this significant medical need.1 The global market for CHIKV vaccines is estimated to exceed $500 million annually by 2032.2
“Today, it is estimated that more than 75% of the world’s population lives in areas at risk of CHIKV transmission due to factors such as global warming and climate change....
Today's Sponsors
Today's Sponsor